Reach Us +1-217-403-9671
Inhibitory Effect Of Bauhinia Rufa On Oxidative Stress And Enzymes Related To Metabolic Syndrome | 82538
ISSN 2472-1042

Pharmacoeconomics: Open Access
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Inhibitory effect of Bauhinia rufa on oxidative stress and enzymes related to metabolic syndrome

Joint Event on 12th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry & 9th Edition of International Conference on Alternative Medicine

Paola dos Santos da Rocha, Jaqueline Ferreira Campos, Vanessa Marina Branco Paula, Valeria Nunes de Souza, Luiza Antas Rabelo, Ana Paula de Araujo Boleti, Maria Leticia Miranda Fernandes Estevinho, Edson Lucas dos Santos and Kely de Picoli Souza

Federal University of Grande Dourados, Brazil Polytechnic Institute of Bragança, Portugal Federal University of Pernambuco, Brazil Federal University of Alagoas, Av. Lourival Melo Mota, Brazil

Posters & Accepted Abstracts: Pharmacoeconomics

DOI: 10.4172/2472-1042-C1-006

The metabolic syndrome is characterized by a set of metabolic risk factors that increase the chance of developing cardiovascular diseases and type 2 diabetes. The present study was carried out to investigate the antioxidant potential and inhibitory of enzymes related to the metabolic syndrome of leaf methanolic extract of Bauhinia rufa (Bong.) Steud. (MEBr). Antioxidant activity was evaluated by DPPH and ABTS free radical scavenging assays, inhibition of β-carotene bleaching, FRAP, reducing power, evaluation of the antioxidant enzyme activity SOD, CAT and GPx, reduction of malonyldialdehyde (MDA) in human erythrocytes and inhibition of formation of advanced glycation products (AGEs) via fructose and via glyoxal. Enzymes related to metabolism investigated were α-amylase, α-glycosidase and lipase. The MEBr (1) presented antioxidant activity in the free radical capture assays DPPH (IC50 8.23±0.46 μg/mL), ABTS (IC50 5.24±0.37 μg/mL), inhibition of β- carotene bleaching (IC50 196.99±20.51 μg/mL), FRAP (EC50 125.88±4.81 μg/mL) and reducing power (EC50 231.11±2.87 μg/mL); (2) stimulated the activity of SOD (16.64±1.40%) in the concentrations of 50 to 250 μg/ mL and did not alter the activity of CAT and GPx; (3) reduced the oxidative stress observed by the lower MDA content generated at concentrations of 75 μg/mL (27.95±7.58%), 100 μg/mL (50.18±2.54%), 125 μg/mL (59.47±6.24%), and 250 μg/ mL (72.81±2.45%); (4) presented anti-glycation activity by reducing fructose-generated AGEs (IC 50 2.76±0.09 μg/ml) and via glyoxal (IC 50 53.13±0.43 μg/mL); and (5) inhibited α-amylase (IC50 6.80±0.09 μg/mL), α-glycosidase (IC50 16.54±0.86 μg/mL) and lipase activity (IC50 65.98±0.55 μg/mL). Taken together, these data reveal the therapeutic potential of MEBr for the prevention and treatment of metabolic disorders.

Paola dos Santos da Rocha is a Biologist and pursuing PhD in Biotechnology and Biodiversity at Federal University of Grande Dourados, MS, Brazil. Her research interests include bioprospecting of medicinal plants and endophytic fungi applied to health bioassays (metabolic syndrome, diabetes, obesity, dyslipidemias, oxidative stress and cancer).